Allergy Immunoassay Market Brief: Sophistication in Testing is Leading to More Automated Effective Testing
25 janv. 2022 05h23 HE
|
Research and Markets
Dublin, Jan. 25, 2022 (GLOBE NEWSWIRE) -- The "Allergy Immunoassay Brief" report has been added to ResearchAndMarkets.com's offering. Allergies are a number of conditions that are caused by...
Intrommune Therapeutics Names Sergi X. Trilla, MD, MBA as its Director, Corporate Strategy & Partnerships
21 déc. 2021 09h39 HE
|
Intrommune Therapeutics
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
AllerSmart IgE Allergy Testing Now Available for At-Home or At-Clinic and Includes the 9 'Big Foods' and 29 Key Environmentals
26 nov. 2021 09h00 HE
|
AllerSmart IgE
VICTORIA, British Columbia, Nov. 26, 2021 (GLOBE NEWSWIRE) -- Covid 19 has dramatically impacted the healthcare industry and as such, antibody diagnostics have quickly evolved and gained...
Intrommune Participates in the Forsyth dentech 2021 Conference
22 sept. 2021 09h30 HE
|
Intrommune Therapeutics
NEW YORK, Sept. 22, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based biotechnology company developing a patient-friendly treatment platform for peanut and other food allergies,...
Intrommune Therapeutics Appoints Gerard Kugel, D.M.D., M.S., Ph.D. to its Scientific Advisory Board
21 sept. 2021 09h30 HE
|
Intrommune Therapeutics
NEW YORK, Sept. 21, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other...
Global Allergy Treatment Markets Report 2021-2026: Allergy Therapeutics and ALK-Abello Dominates the Immunotherapy Segment
21 sept. 2021 05h53 HE
|
Research and Markets
Dublin, Sept. 21, 2021 (GLOBE NEWSWIRE) -- The "Allergy Treatment Market - Global Outlook & Forecast 2021-2026" report has been added to ResearchAndMarkets.com's offering. The allergy treatment...
Intrommune Therapeutics Announces Arrival of Stuart Loesch as New CCO
08 sept. 2021 10h02 HE
|
Intrommune Therapeutics
NEW YORK, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, Inc., a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and...
Intrommune Therapeutics Launches #PeanutAllergyStrong
24 août 2021 12h25 HE
|
Intrommune Therapeutics
NEW YORK, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Intrommune Therapeutics Appoints Moises V. “Moe” Vela, Jr. to its Business Advisory Board
11 août 2021 13h37 HE
|
Intrommune Therapeutics
NEW YORK, Aug. 11, 2021 (GLOBE NEWSWIRE) -- Intrommune Therapeutics, a New York-based, clinical stage biotechnology company developing a patient-friendly treatment platform for peanut and other food...
Global Food Allergy and Intolerance Products Market Report 2021: Market to Reach $32 Billion by 2027 - Broad Availability of Products Encourage Market Growth
09 août 2021 08h08 HE
|
Research and Markets
Dublin, Aug. 09, 2021 (GLOBE NEWSWIRE) -- The "Food Allergy and Intolerance Products - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering. Global...